Trial Profile
A Phase II, Double-blind, Randomized, Placebo-controlled, Multicenter Trial to Assess the Efficacy and Safety of Neu2000KWL in Patients Who Resuscitated After Out-of-hospital Cardiac Arrest Patient and Receiving Therapeutic Hypothermia
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Aug 2022
Price :
$35
*
At a glance
- Drugs Nelonemdaz (Primary)
- Indications Heart arrest
- Focus Therapeutic Use
- Acronyms AWAKE
- Sponsors GNT Pharma
- 23 Jul 2022 Trial design published in the Trials.
- 05 Mar 2019 Status changed from not yet recruiting to recruiting.
- 06 Sep 2018 New trial record